| URL | https://www.pharmaceutical-technology.com/news/bay |
| Source | Pharmaceutical Technology |
| Date Published | 10/10/2023 |
| Company/Division name | Bayer |
| Parent company | Bayer |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2023 |
| Capital investment ($): | 250 |
| Country(ies) from which reshored: | Germany |
| City reshored to: | Berkeley |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | cell therapies pharmaceuticals |
| What domestic positive factors made reshoring more attractive? | Manufacturing/engineering joint innovation (R&D) |